Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Drug Developers Researching Messenger RNA Replacement Therapies

By BiotechDaily International staff writers
Posted on 18 Apr 2013
Drug developers are showing increased interest in the use of messenger RNA (mRNA) as an alternate to gene replacement therapy.

A review in the April 2, 2013, online edition of the journal MIT Technology Review highlighted several companies planning or initiating research projects on the pharmaceutical applications of mRNA.

These molecules are attractive, as an mRNA would supply the biological instructions for producing a protein inside cells, perhaps a protein that replaces a missing or broken version inherited as part of a genetic disorder. This would be more efficient than DNA-based gene therapy (which would require the cells to make their own mRNA intermediary before producing a protein) and more effective than recombinant protein therapy. Proteins made from an injected mRNA would be less likely to induce an immune response than if the proteins were made in bacteria or yeast. Furthermore, more active drug would be available, as large scale in vitro manufacture of some proteins is not possible.

Obstacles that might hinder development of mRNA-based therapeutics include the fragility of these molecules and their tendency to generate a powerful immune response. However, companies beginning work in this field are confident they can overcome these difficulties. For example, Moderna Therapeutics (Cambridge, MA, USA) has modified mRNA by replacing nucleotides, so that the immune system no longer recognizes the molecule as dangerous. Their success so far has convinced the major pharmaceutical company AstraZeneca (London, United Kingdom) to pay USD 240 million for rights to the startup’s mRNA technology, which it hopes to use to develop treatments for cardiovascular, metabolic, and cancer patients.

Nucleotide substitutions seem to correct the problem of mRNA fragility. “Everybody considers mRNA to be the most unstable molecule you can think of,” said Dr. Christian Plank, CSO of Ethris (Martinsried, Germany), a company also developing modified mRNAs as drugs. “This opinion is still in the minds of most people and is a major reason why only a few people have thought of using it.” Fortunately, mRNA made with nucleotide analogs are more stable, and have been shown to last for up to 72 hours in the body, which is longer than for some protein therapies.

Molecules of mRNA cannot integrate into the genome and so do not present the same risk of disrupting the genome that DNA-based gene therapies do. “In general, gene therapy is a good approach, and in recent years there have been good breakthroughs, but for non-life-threatening disease, you want to avoid any potential risk you can think of, and integration into the genome is a known risk,” said Dr. Plank.

Ethris recently announced a collaborative agreement with the pharmaceutical company Shire (Dublin, Eire) to develop treatments for patients with rare diseases based on its technology.

Related Links:
Moderna Therapeutics
AstraZeneca
Ethris



Channels

Genomics/Proteomics

view channel
Image: Pluristem technicians produce PLacental eXpanded (PLX) cells in the company\'s state-of-the-art facility (Photo courtesy of Pluristem Therapeutics).

Placental Cells Secrete Factors That Protect Nerves from Ischemic Damage

Cells derived from placenta have been found to protect PC12 cells—rat-derived cells that behave similarly to and are used as stand-ins to study human nerve cells—in a culture-based ischemic stroke model.... Read more

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Program Designed to Provide High-Performance Computing Cluster Systems for Bioinformatics Research

Dedicated Computing (Waukesha, WI, USA), a global technology company, reported that it will be participating in the Intel Cluster Ready program to deliver integrated high-performance computing cluster solutions to the life sciences market. Powered by Intel Xeon processors, Dedicated Computing is providing a range of... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.